PT  - JOURNAL ARTICLE
AU  - Joaquim Mullol
AU  - Giorgio Walter Canonica
AU  - Martin Wagenmann
AU  - Andre Coste
AU  - Peter Hellings
AU  - Scott Nash
AU  - Siddhesh Kamat
AU  - Urvi Mujumdar
AU  - Jérôme Msihid
AU  - Asif H Khan
AU  - Shahid Siddiqui
AU  - Juby A Jacob-Nara
AU  - Yamo Deniz
AU  - Paul Rowe
TI  - SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials
AID  - 10.1183/13993003.congress-2021.PA2520
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA2520
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA2520.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA2520.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Background: Chronic rhinosinusitis with nasal polyps is a predominantly type-2 mediated inflammatory disease with high symptom and quality of life burden. Dupilumab significantly improved 22-item Sino-Nasal Outcome Test (SNOT-22) total score vs placebo (PBO) in SINUS-24 and SINUS-52 trials (NCT02912468; NCT02898454).Objectives: Post hoc analysis of pooled SINUS-24 and SINUS-52 to identify the SNOT-22 items most important to patients (pts), assess the effect of dupilumab on these items, and association with objective disease measures.Methods: Nasal polyp (NPS) and Lund-Mackay (LMK) scores were assessed in pts with and without improvement at Wk 24 in the SNOT-22 items ranked most important by pts at baseline (BL).Results: Decreased sense of smell/taste and nasal blockage were the most important SNOT-22 items at BL (cited important by 87% and 82% of pts, respectively). More dupilumab (N=438) vs PBO (N=286) pts improved in these items at Wk 24 (smell/taste: 76.7% vs 30.4%; nasal blockage: 79.5% vs 44.4%). Dupilumab significantly improved NPS and LMK in all pts regardless of improvement in SNOT-22 items, with the greatest treatment effect seen in pts who had an improvement (Table below).Conclusions: A higher percentage of dupilumab-treated pts improved in symptoms most important to pts (smell/taste; nasal blockage) vs PBO. Improvement in these symptoms signals greater improvement in objective measures (LMK and NPS). SNOT-22 item improvement (Wk 24)Least squares mean difference vs PBO (Wk 24)Smell/tasteYes/noNasal blockageYes/noNPS–1.78*/–1.19*–1.90*/–1.01*LMK–5.77*/–4.26*–6.22*/–3.28**P<0.0001 vs PBOFootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2520.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).